Lmax and imiquimod 3.75%: The new standard in AK management

Journal of the European Academy of Dermatology and Venereology

Volumn 29, Issue s1, 2015, Pages 9-14

  Stockfleth, E ^a  

^a ST JOSEF HOSPITAL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOQUINOLINE DERIVATIVE; IMIQUIMOD; IMMUNOLOGICAL ADJUVANT;

HUMAN; KERATOSIS, ACTINIC;

ADJUVANTS, IMMUNOLOGIC; AMINOQUINOLINES; HUMANS; KERATOSIS, ACTINIC;

EID: 84914126690     PISSN: 09269959     EISSN: 14683083     Source Type: Journal    
DOI: 10.1111/jdv.12824     Document Type: Review

References (39)

1. Stockfleth E,. The paradigm shift in treating actinic keratosis: a comprehensive strategy. J Drugs Dermatol 2012; 11: 1462-1467.
2. Berman B, Bienstock L, Kuritzky L, Mayeaux EJ Jr, Tyring SK. Actinic keratoses: sequelae and treatments. Recommendations from a consensus panel. J Fam Pract 2006; 55 (Suppl): 1-8.
3. Ibrahim SF, Brown MD,. Actinic keratoses: a comprehensive update. J Clin Aesthet Dermatol 2009; 2: 43-48.
4. Fenske NA, Spencer J, Adam F,. Actinic keratoses: past, present and future. J Drugs Dermatol 2010; 9: s45-s49.
5. Kennedy C, Bajdik CD, Willemze R, De Gruijl FR, Bouwes Bavinck JN,. The influence of painful sunburns and lifetime sun exposure on the risk of actinic keratoses, seborrheic warts, melanocytic nevi, atypical nevi, and skin cancer. J Invest Dermatol 2003; 120: 1087-1093.
6. Frost CA, Green AC, Williams GM,. The prevalence and determinants of solar keratoses at a subtropical latitude (Queensland, Australia). Br J Dermatol 1998; 139: 1033-1039.
7. Stockfleth E, Ortonne JP, Alomar A,. Actinic keratosis and field cancerisation. Eur J Dermatol 2011; 21 (Suppl 1): 3-12.
8. Ulrich M, Krueger-Corcoran D, Roewert-Huber J, Sterry W, Stockfleth E, Astner S,. Reflectance confocal microscopy for noninvasive monitoring of therapy and detection of subclinical actinic keratoses. Dermatology 2010; 220: 15-24.
9. Ortonne JP, Gupta G, Ortonne N, Duteil L, Queille C, Mallefet P,. Effectiveness of cross polarized light and fluorescence diagnosis for detection of sub-clinical and clinical actinic keratosis during imiquimod treatment. Exp Dermatol 2010; 19: 641-647.
10. Green A, Battistutta D,. Incidence and determinants of skin cancer in a high-risk Australian population. Int J Cancer 1990; 46: 356-361.
11. Feldman SR, Fleischer AB Jr,. Progression of actinic keratosis to squamous cell carcinoma revisited: clinical and treatment implications. Cutis 2011; 87: 201-207.
12. Stockfleth E, Ferrandiz C, Grob JJ, Leigh I, Pehamberger H, Kerl H,. Development of a treatment algorithm for actinic keratoses: a European Consensus. Eur J Dermatol 2008; 18: 651-659.
13. Stockfleth E, Gupta G, Peris K, Aractingi S, Dakovic R, Alomar A,. Reduction in lesions from Lmax: a new concept for assessing efficacy of field-directed therapy for actinic keratosis. Results with imiquimod 3.75%. Eur J Dermatol 2014; 24: 23-27.
14. Gupta AK, Cooper EA, Abramovits W,. Zyclara (imiquimod) cream, 3.75%. Skinmed 2010; 8: 227-229.
15. Quist SR, Gollnick HP,. Imiquimod 3.75% cream (Zyclara) for the treatment of actinic keratoses. Expert Opin Pharmacother 2011; 12: 451-461.
16. Swanson N, Abramovits W, Berman B, Kulp J, Rigel DS, Levy S,. Imiquimod 2.5% and 3.75% for the treatment of actinic keratoses: results of two placebo-controlled studies of daily application to the face and balding scalp for two 2-week cycles. J Am Acad Dermatol 2010; 62: 582-590.
17. Swanson N, Smith CC, Kaur M, Goldenberg G,. Imiquimod 2.5% and 3.75% for the treatment of actinic keratoses: two phase 3, multicenter, randomized, double-blind, placebo-controlled studies. J Drugs Dermatol 2014; 13: 166-169.
18. Lebwohl M, Swanson N, Anderson LL, Melgaard A, Xu Z, Berman B,. Ingenol mebutate gel for actinic keratosis. N Engl J Med 2012; 366: 1010-1019.
19. Alomar A, Bichel J, McRae S,. Vehicle-controlled, randomized, double-blind study to assess safety and efficacy of imiquimod 5% cream applied once daily 3 days per week in one or two courses of treatment of actinic keratoses on the head. Br J Dermatol 2007; 157: 133-141.
20. Jorizzo J, Dinehart S, Matheson R, et al,. Vehicle-controlled, double-blind, randomized study of imiquimod 5% cream applied 3 days per week in one or two courses of treatment for actinic keratoses on the head. J Am Acad Dermatol 2007; 57: 265-268.
21. Rivers JK, Arlette J, Shear N, Guenther L, Carey W, Poulin Y,. Topical treatment of actinic keratoses with 3.0% diclofenac in 2.5% hyaluronan gel. Br J Dermatol 2002; 146: 94-100.
22. Wolf JE Jr, Taylor JR, Tschen E, Kang S,. Topical 3.0% diclofenac in 2.5% hyaluronan gel in the treatment of actinic keratoses. Int J Dermatol 2001; 40: 709-713.
23. Krawtchenko N, Roewert-Huber J, Ulrich M, Mann I, Sterry W, Stockfleth E,. A randomised study of topical 5% imiquimod vs. topical 5-fluorouracil vs. cryosurgery in immunocompetent patients with actinic keratoses: a comparison of clinical and histological outcomes including 1-year follow-up. Br J Dermatol 2007; 157 (Suppl 2): 34-40.
24. Gupta AK,. The management of actinic keratoses in the United States with topical fluorouracil: a pharmacoeconomic evaluation. Cutis 2002; 70: 30-36.
25. Szeimies RM, Karrer S, Radakovic-Fijan S, et al,. Photodynamic therapy using topical methyl 5-aminolevulinate compared with cryotherapy for actinic keratosis: a prospective, randomized study. J Am Acad Dermatol 2002; 47: 258-262.
26. Piacquadio DJ, Chen DM, Farber HF, et al,. Photodynamic therapy with aminolevulinic acid topical solution and visible blue light in the treatment of multiple actinic keratoses of the face and scalp: investigator-blinded, phase 3, multicenter trials. Arch Dermatol 2004; 140: 41-46.
27. Gaspari AA,. Mechanism of action and other potential roles of an immune response modifier. Cutis 2007; 79: 36-45.
28. Sauder DN,. Immunomodulatory and pharmacologic properties of imiquimod. J Am Acad Dermatol 2000; 43: S6-S11.
29. Lacarrubba F, Nasca MR, Micali G,. Advances in the use of topical imiquimod to treat dermatologic disorders. Ther Clin Risk Manag 2008; 4: 87-97.
30. Schiller M, Metze D, Luger TA, Grabbe S, Gunzer M,. Immune response modifiers-mode of action. Exp Dermatol 2006; 15: 331-341.
31. Schon M, Bong AB, Drewniok C, et al,. Tumor-selective induction of apoptosis and the small-molecule immune response modifier imiquimod. J Natl Cancer Inst 2003; 95: 1138-1149.
32. Torres A, Storey L, Anders M, et al,. Immune-mediated changes in actinic keratosis following topical treatment with imiquimod 5% cream. J Transl Med 2007; 5: 7.
33. Stockfleth E,. Long-term sustained lesion clearance from Lmax with imiquimod 3.75%, a new field-directed treatment for actinic keratosis. Poster presented at EADV 2013 Abstract P0384.
34. Hanke CW, Swanson N, Bruce S, Berman B, Kulp J, Levy S,. Complete clearance is sustained for at least 12 months after treatment of actinic keratoses of the face or balding scalp via daily dosing with imiquimod 3.75% or 2.5% cream. J Drugs Dermatol 2011; 10: 165-170.
35. Gupta G,. Imiquimod 3.75% and risk of progression to squamous cell carcinoma from actinic keratosis: case studies of potential benefit. Poster presented at EADV 2012 Abstract P0504.
36. Gupta G,. Effective clearance of actinic keratosis with imiquimod 3.75%: case study confirming the need for repeat immune stimulation with two treatment cycles. Poster presented at EADV 2012 Abstract P0503.
37. Werschler WP,. Considerations for use of Fluorouracil cream 0.5% for the treatment of actinic keratosis in elderly patients. J Clin Aesthet Dermatol 2008; 1: 22-27.
38. Claesson S, Morrison A, Wertheimer AI, Berger ML,. Compliance with prescribed drugs: challenges for the elderly population. Pharm World Sci 1999; 21: 256-259.
39. Alomar A,. Efficacy of imiquimod 3.75% from Lmax in patients with and without rest periods during treatment. Poster presented at EADV 2013 Abstract P0536.